Ovid Therapeutics shares rise 10.10% intraday as company develops small-molecule drugs for brain diseases with significant unmet needs.

viernes, 20 de marzo de 2026, 11:38 am ET1 min de lectura
OVID--
Ovid Therapeutics surged 10.10% intraday, as the company focuses on developing small molecules for brain diseases targeting areas with significant unmet needs. The biopharmaceutical firm specializes in innovative therapies for neurological conditions where patient demand remains largely unaddressed.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios